HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK's Maxwellia Offers Mid-Price Branded Levonorgestrel Alternative

Executive Summary

UK consumers will soon be able to purchase at an "accessible" price branded levonorgestrel-based emergency contraceptive, LoviOne, marketed by switch specialists Maxwellia. 

You may also be interested in...



HRA Pharma And Maxwellia To Launch The UK’s First OTC Daily Contraceptives

The UK's MHRA has approved the Rx-to-OTC switch of two identical progestogen-only contraceptive pills from HRA Pharma and Maxwellia. Hana and Lovima (both 75mcg desogestrel) will be launched at the end of the month. 

Why Are UK CBD Brands Pivoting Into Functional Mushroom Supplements?

Ongoing regulatory issues and restrictive marketing rules are prompting CBD brands to pivot to functional mushrooms, the market for which in the UK is predicted to reach a value of £62m by 2025. With both reportedly offering cognitive health benefits, marketing mushrooms and CBD makes good strategic sense, explains Nootro Group CEO Cary Holmes in this HBW Insight deep dive. 

Haleon Helps Pharmacists #ListentoPain As Social Stigma And Isolation Increases

Haleon finds in its latest global “Pain Index” that people are becoming less tolerant and more judgmental. To help remedy this situation, the firm has launched a training program to support pharmacists to “improve communication with patients and have a focused discussion on pain tailored to the individual.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154017

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel